Novo Nordisk ADR (NVO) saw an uptrend of 4.76% in the recent trading with $51.08 being its most recent. The current price level -63.45% lower than the highest price of $139.74 marked by the stock while trading over the past 52-weeks, whereas it is 13.39% higher than the lowest price of $45.05 the company dropped to over past 52-weeks. The latest news story on NVO appeared in (Motley Fool) under the title “2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 5 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.25 for the stock.
Novo Nordisk ADR Earnings – What Happened With NVO
Coming around sales and income figures on NVO Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Novo Nordisk ADR (NVO) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 3.44% for net revenue.
NVO – Novo Nordisk ADR Stock Earnings Estimates
The perspective of Novo Nordisk ADR (NYSE:NVO)’s current quarter earnings identifies that analysts are in consensus over the estimate of 5.92 for stock’s EPS in the current quarter. Novo Nordisk ADR (NVO) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 3.44% for net revenue. Company’s EPS for the last quarter was 6.12.
Novo Nordisk ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 3.37 billion. NVO does have institutional investors; and they hold 9.67% of the stock.
As on 2024-06-30, JENNISON ASSOCIATES LLC was the top most holder in Novo Nordisk ADR (NYSE:NVO) with an ownership of 21.22 million shares of the company or 0.476 of the stake worth $3.03 billion. The filing also reveals FMR LLC as the second largest holder in the company with a control over 0.4373 of the outstanding shares. Its stake is worth $2.78 billion for having 19.49 million shares in hand.
MORGAN STANLEY also came holding a key position in the company during the recent quarter and it now holds 0.3272 of the outstanding shares. With this there are now 1764.0 institutions which have possession in NVO’s shares.
Key Metrics forNVO
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Novo Nordisk ADR has a debt to equity ratio of 0.59.
